TBRG

TruBridgeA

Nasdaq / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

38%

Probability

Target price

$26.25

+1.1% vs current

Most likely

Base case

42%

Probability

Target price

$25.95

-0.0% vs current

B-

Bear case

20%

Probability

Target price

$22.00

-15.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-16

AI commentary

This was a T+3 earnings follow-up run, but the company source checked shows the actual earnings filing date was May 8, 2026, not May 13, 2026. The key post-print takeaway is that the May 8 filing preserved the Q3 2026 cash-close framework and did not show an obvious operating break. By the May 15, 2026 anchor, shares at $25.86 were still only modestly below the $26.25 cash consideration, implying limited new reaction beyond normal spread trading. Trusted post-earnings analyst revision evidence was not available in the checked packet and sources, so this remains a cautious monitoring view rather than a stronger fundamental call.

RankAlpha Sentiment Codex - 2026-05-16

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystQ1 results support deal stability but did not create new upsideMedium impact

Q1 2026 revenue was $86.3 million versus $87.2 million a year earlier, total bookings rose to $17.7 million from $17.3 million, Patient Care revenue excluding Centriq rose to $32.5 million from $30.0 million, and cash increased to $35.4 million from $24.9 million at year-end. That mix suggests the business remained stable enough after the May 8, 2026 earnings release, but it does not obviously justify value above the fixed cash takeout. [#10-Q-2026-05-08] [#8-K-2026-05-08]

2026-09-30eventCash merger close remains the main near-term driverMedium impact

TruBridge's March 31, 2026 10-Q says each share will convert into $26.25 in cash at closing, subject to stockholder approval, HSR clearance, and other conditions. With the May 15, 2026 anchor price at $25.86, most upside is now spread compression into the expected Q3 2026 close rather than a fresh operating rerating. [#10-Q-2026-05-08]

2026-10-23catalystMerger-condition and break-risk language still caps convictionHigh impact

The 10-Q says the merger can be terminated if it is not completed by October 23, 2026 and notes a required TopCo shareholder approval tied to debt financing by June 22, 2026; it also discloses an approximately $12.3 million company termination fee, a $24.6 million reverse termination fee, and warns that failure or delay could pressure the stock. That keeps the setup event-driven and makes the standalone fallback materially weaker than the cash-close case. [#10-Q-2026-05-08]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-16 • Updated nightlySource: Internal modelMethodology